Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
GHK-Cu is the copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine. Laboratory evidence is extensive, while formulation-specific human evidence is more limited.
Key points
- The compound is a copper-binding tripeptide complex also called copper tripeptide-1.
- Evidence from cells, animals and humans must be interpreted separately.
- GHK-Cu is used in some cosmetic formulations, but this does not authorise independently supplied material for administration or therapeutic use.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
GHK-Cu is the copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine. Laboratory evidence is extensive, while formulation-specific human evidence is more limited. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
GHK binds copper(II), which may affect copper transport and extracellular-matrix signalling. Cell studies have examined collagen expression, metalloproteinases and oxidative responses, but biological effects depend on concentration, formulation and model.
What does the current evidence show?
- Early fibroblast experiments reported stimulation of collagen synthesis under controlled culture conditions.
- Ex-vivo human-skin work has examined penetration by copper-tripeptide species.
- Small topical studies are discussed in reviews, but they do not establish the effects or safety of other routes or formulations.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Much of the literature is old, preclinical or formulation-specific.
- Topical cosmetic evidence cannot be generalised to injectable or lyophilised research material.
- Copper speciation, purity and delivery conditions can materially alter experimental behaviour.
Regulatory and safety context
GHK-Cu is used in some cosmetic formulations, but this does not authorise independently supplied material for administration or therapeutic use. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.